The Life Sciences team represented Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) in its definitive merger agreement with Akebia Therapeutics, Inc. (NASDAQ:AKBA) under which the companies will combine in an all-stock merger. The transaction will create a fully integrated biopharmaceutical company focused on chronic kidney disease (CKD), with an implied pro forma equity value of approximately $1.3 billion, assuming full conversion of Keryx’s outstanding convertible notes, based on the closing prices of Keryx and Akebia on June 27, 2018. The combined company will be named Akebia Therapeutics, Inc.
The transaction is expected to close by the end of 2018, subject to the satisfaction of customary closing conditions, including clearance by antitrust authorities and approval by the shareholders of both companies.
Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team works with passion to advance the care of people with this complex disease.
The Goodwin team was led by partners Stuart Cable and Jacqueline Mercier and associate Yasin Akbari and included partner Deborah Birnbach, associates Leo Martin, Rob Intile, Jr., Fabiola Valenzuela and Morgan Mordecai.
For additional details on the merger, please read the press release.